Stemirna Therapeutics Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Stemirna Therapeutics Co., Ltd. - overview
Established
2016
Location
Shanghai, Shanghai, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and established in 2016, Stemirna Therapeutics Co. , Ltd. is a biotechnology company that specializes in mRNA technology. Li Hangwen is the founder and current CEO of the company.
It has partnerships with Baidu USA Research Institute, Oregon State University, and the University of Rochester. Following the venture funding in June 2021, the company plans to use the proceeds to finance clinical trials and the production of its COVID-19 vaccine candidate. In May 2023, t raised an undisclosed amount of pre-series D funding from other unspecified investors. The company has 50,000 square meters of vaccine production base and 400 million doses of vaccine capacity as of 2023.
The company focuses on developing and providing mRNA (mRNA stands for messenger RNA, it is the information carrier in the process of gene expression) drugs for different diseases, including cancer, contagion, and a genetic disorder. The company's platforms include an mRNA synthesis platform, an LPP (ipopolyplex) delivery platform, and GMP manufacturing (GMP-compliant facilities for manufacturing and quality control). The company has also developed a pipeline that spans different therapeutic areas, including immuno-oncology, infectious diseases, and iPSC, based on its mRNA synthesis platform and LPP delivery platform.
Current Investors
Lapam Capital, Puhong Capital, Zhuhai Longmen Capital Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.stemirna.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Stemirna Therapeutics Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Stemirna Therapeutics Co., Ltd. | - | ||||||||
| Unspecified Round | Completed | Stemirna Therapeutics Co., Ltd. | - | ||||||||
| Unspecified Round | Completed | Stemirna Therapeutics Co., Ltd. | - | ||||||||
| Series A | Completed | Stemirna Therapeutics Co., Ltd. | - | ||||||||
| Series A | Completed | Stemirna Therapeutics Co., Ltd. | - |
Displaying 1 - 5 of 7
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.